Activating mutations of
We performed a retrospective and unicentric analysis of
189 samples were analyzed in 155p with HR+/HER2- BC (128 in tissue & 61 in plasma).
56 [24-91] 45(76.3%) 85(81.7%) 12(20.3%) 6(5.8%) 2(3.4%) 13(12.5%) 19(34.5%) 17(17%) 30(54.6%) 65(66%) 6(10.9%) 18(18%) 28(50%) 52(50.9%) P=0.91 28(50%) 50(49.1%) 41(74.5%) 88(85.4%) P=0.09 14(25.5%) 15(14.6%) 19(41.3%) 29(32,6%) P=0.31 27(58.7%) 60(67.4%) 10(34.5%) 21(38.2%) P=0.73 19(65.5%) 34(61.8%) 24(82.8%) 40 (72.7%) P=0.31 5(17.2%) 15(27.3%)
Mutational spectrum and clinical features in
The authors.
Has not received any funding.
C.A. Rodríguez Sanchez: Non-Financial Interests, Institutional, Advisory Role: Novartis, Lilly, Pfizer, Roche, Daiichi Sankyo, AstraZeneca, MSD, Veracyte, Gilead. All other authors have declared no conflicts of interest.